Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt

References

• DunnCJWagstaffAJPerryCMPloskerGLGoaKLCyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral®) in organ transplantationDrugs200161131957201611708766
   PubMed Web of Science ®Google Scholar
• DentonMDMageeCCSayeghMHImmunosuppressive strategies in transplantationLancet199935391581083109110199367
   PubMed Web of Science ®Google Scholar
• NobleSMarkhamACyclosporine: a review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral®)Drugs19955059249418586033
   PubMed Web of Science ®Google Scholar
• CzogallaAOral cyclosporine A – the current picture of its liposomal and other delivery systemsCell Mol Biol Lett200914113915219005620
   PubMed Web of Science ®Google Scholar
• HebertMFContributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug deliveryAdv Drug Deliv Rev1997272–320121410837558
   PubMed Web of Science ®Google Scholar
• GuoJXPingQNChenYPharmacokinetic behavior of cyclosporin A in rabbits by oral administration of lecithin vesicle and sandimmun neoralInt J Pharm20012161–2172111274802
   PubMed Web of Science ®Google Scholar
• MüllerRHRungeSRavelliVMehnertWThünemannAFSoutoEBOral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN®) versus drug nanocrystalsInt J Pharm20063171828916580159
   PubMed Web of Science ®Google Scholar
• ItaliaJLBhattDKBhardwajVTikooKKumarMPLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral®J Control Release2007119219720617399839
   PubMed Web of Science ®Google Scholar
• DaiJDNagaiTWangXQZhangTMengMZhangQpH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine AInt J Pharm20042801–222924015265562
   PubMed Web of Science ®Google Scholar
• WangXQHuangJDaiJDLong-term studies on the stability and oral bioavailability of cyclosporine A nanoparticle colloidInt J Pharm20063221–214615316787721
   PubMed Web of Science ®Google Scholar
• HermidaLGSabés-XamaníMBarnadas-RodríguezRCombined strategies for liposome characterization during in vitro digestionJ Liposome Res200919320721919548842
   PubMed Web of Science ®Google Scholar
• AndrieuxKForteLLesieurSPaternostreMOllivonMGrabielle-MadelmontCSolubilisation of dipalmitoylphosphatidylcholine bilayers by sodium taurocholate: A model to study the stability of liposomes in the gastrointestinal tract and their mechanism of interaction with a model bile saltEur J Pharm Biopharm200971234635518835441
   PubMed Web of Science ®Google Scholar
• WerleMTakeuchiHChitosan-aprotinin coated liposomes for oral peptide delivery: Development, characterisation and in vivo evaluationInt J Pharm20093701–2263219073243
   PubMed Web of Science ®Google Scholar
• AminMJaafariMRTafaghodiMImpact of chitosan coating of anionic liposomes on clearance rate, mucosal and systemic immune responses following nasal administration in rabbitsColloid Surface B2009741225229
   Web of Science ®Google Scholar
• ParkHJLeeCMLeeYBLeeKYControlled release of cyclosporin A from liposomes-in-microsphere as an oral delivery systemsBiotechnol Bioproc Eng2006116526529
   Web of Science ®Google Scholar
• LeeJ-SChungDLeeHGPreparation and characterization of calcium pectinate gel beads entrapping catechin-loaded liposomesInt J Biol Macromol200842217818418022686
   PubMed Web of Science ®Google Scholar
• ConacherMAlexanderJBrewerJMOral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes)Vaccine20011920–222965297411282208
   PubMed Web of Science ®Google Scholar
• SeniorKBilosomes: the answer to oral vaccine delivery?Drug Discov Today20016201031103211590024
   PubMed Web of Science ®Google Scholar
• ShuklaAKhatriKGuptaPNGoyalAKMehtaAVyasSPOral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes)J Pharm Pharmaceut Sci20081115866
   Web of Science ®Google Scholar
• MannJFSFerroVAMullenABOptimisation of a lipid based oral delivery system containing A/Panama influenza haemagglutininVaccine200422192425242915193405
   PubMed Web of Science ®Google Scholar
• ChenYPLuYChenJMEnhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile saltInt J Pharm20093761–215316019394416
   PubMed Web of Science ®Google Scholar
• HildebrandABeyerKNeubertRGaridelPBlumeATemperature dependence of the interaction of cholate and deoxycholate with fluid model membranes and their solubilization into mixed micellesColloid Surface B2003324335351
   Web of Science ®Google Scholar
• ClarkMAJepsonMAHirstBHExploiting M cells for drug and vaccine deliveryAdv Drug Deliv Rev2001501–28110611489335
   PubMed Web of Science ®Google Scholar
• TangNLaiJChenYLuYWuWFenofibrate solid dispersion pellets prepared by fluid-bed coating: physical characterization, improved dissolution and oral bioavailability in beagle dogsJ Chin Pharm Sci200918156161
   Google Scholar
• YuLXAmidonGLPolliJEBiopharmaceutics classification system: the scientific basis for biowaiver extensionsPharm Res200219792192512180542
   PubMed Web of Science ®Google Scholar
• LiuCWuJHShiBZhangYXGaoTKPeiYYEnhancing the bioavailability of cyclosporine a using solid dispersion containing polyoxyethylene (40) stearateDrug Dev Ind Pharm200632111512316455610
   PubMed Web of Science ®Google Scholar
• GeusensBLambertJDe SmedtSCBuyensKSandersNNVan GeleMUltradeformable cationic liposomes for delivery of small interfering RNA (siRNA) into human primary melanocytesJ Control Release2009133321422018973779
   PubMed Web of Science ®Google Scholar
• NiuGQCogburnBHughesJPreparation and characterization of doxorubicin liposomesGrobmyerSRMoudgilBMCancer Nanotechnology Methods and ProtocolsNew YorkHumana Press2010624211219
   Google Scholar
• LaiJLuYYinZHuFWuWPharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticlesInt J Nanomedicine20105132320161984
   PubMed Web of Science ®Google Scholar
• SunWTZouWWHuangGHLiAGZhangNPharmacokinetics and targeting property of TFu-loaded liposomes with different sizes after intravenous and oral administrationJ Drug Target200816535736518569280
   PubMed Web of Science ®Google Scholar
• YangLYangWZBiDZZengQA novel method to prepare highly encapsulated interferon-alpha-2b containing liposomes for intramuscular sustained releaseEur J Pharm Biopharm200664191516797953
   PubMed Web of Science ®Google Scholar
• NiuMLuYHovgaardLWuWLiposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization and improved protection against enzymatic degradationInt J Nanomedicine20116 in press
   Web of Science ®Google Scholar
• ChingunpitakJPuttipipatkhachornSChavalitshewinkoon-PetmitrPTozukaYMoribeKYamamotoKFormation, physical stability and in vitro antimalarial activity of dihydroartemisinin nanosuspensions obtained by co-grinding methodDrug Dev Ind Pharm200834331432218363147
   PubMed Web of Science ®Google Scholar
• SunJKDengYGWangSLCaoJNGaoXFDongXDLiposomes incorporating sodium deoxycholate for hexamethylmelamine (HMM) oral delivery: Development, characterization, and in vivo evaluationDrug Deliv201017316417020196698
   PubMed Web of Science ®Google Scholar
• ElorzaMAElorzaBChantresJRStability of liposomal formulations: action of amphiphilic moleculesInt J Pharm19971582173183
   Web of Science ®Google Scholar
• WangXQDaiJDChenZBioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administrationJ Control Release200497342142915212874
   PubMed Web of Science ®Google Scholar
• SongKHChungSJShimCKEnhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile saltsJ Control Release2005106329830815979756
   PubMed Web of Science ®Google Scholar